Editorial: Minimally invasive techniques in benign prostatic hyperplasia (BPH) surgery
نویسندگان
چکیده
EDITORIAL article Front. Urol., 30 December 2022Sec. Male Urology Volume 2 - 2022 | https://doi.org/10.3389/fruro.2022.1115743
منابع مشابه
Benign Prostatic Hyperplasia (bph)
Comprehensive studies show that the holmium laser is ideal for treating BPH. Holmium laser treatments have been the most rigorously investigated BPH techniques. Over 90 articles have been published from 8 randomized clinical trials and over 30 case studies and comparative series. The American, European, British and Australasian urology associations recommend holmium laser for BPH treatment. Hol...
متن کاملUpdate on minimally invasive surgery and benign prostatic hyperplasia
Transurethral resection of the prostate (TURP) became the gold standard surgical treatment for benign prostatic obstruction without undergoing randomized controlled trials against the predecessor standard in open suprapubic prostatectomy. TURP has historically been associated with significant morbidity and this has fuelled the development of minimally invasive surgical treatment options. Improv...
متن کاملSurgical Options for Benign Prostatic Hyperplasia (BPH)
In 1788 John Hunter first described the pathology of prostatic hyperplasia and its effects on the upper urinary tract. It took a century for the first suprapubic prostatectomy to be carried out in 1887 by AF McGill in Leeds (though Americans tend to claim credit to Fuller in New York in 1894.) The procedure was subsequently p o p u l a r i s e d b y S i r Pe t e r F r e ye r . R e t r o p u b i...
متن کاملUroLift: a new minimally-invasive treatment for benign prostatic hyperplasia.
'UroLift' has emerged as a new minimally-invasive nonablative surgical technique for benign prostatic hyperplasia (BPH). We discuss the procedure, cost, evidence, advantages and disadvantages of this procedure. It is a novel technology suitable for a selected group of patients that allows for a bespoke treatment for men with BPH.
متن کاملUpdate on minimally invasive therapies for benign prostatic hyperplasia.
Benign prostatic hyperplasia (BPH) is, and will remain, increasingly common with aging. Histologically it has been identified in 50% of patients by age 50, and in 80% of 80 year olds. The excessive growth of prostatic stromal and epithelial cells causes benign prostatic enlargement (BPE). With continued growth, however, BPE can evolve into benign prostatic obstruction (BPO), a condition often a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in urology
سال: 2022
ISSN: ['2673-9828']
DOI: https://doi.org/10.3389/fruro.2022.1115743